血清肺腺癌转移相关转录本1水平与非小细胞肺癌放射治疗效果的关系研究  

Relationship between serum metastasis-associated lung adenocarcinoma transcript 1 level and the radiotherapy effect on non-small cell lung cancer

作　　者：叶承逾 马胜林[1] 夏冰 林权冰 金璋 郑翠苹 徐志娜 Ye Chengyu;Ma Shenglin;Xia Bing;Lin Quanbing;Jin Zhang;Zheng Cuiping;Xu Zhina(Binwen Campus of Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang Province,China;Department of Radiotherapy,Hangzhou First People's Hospital Affiliated to Zhejiang Chinese Medical University,Hangzhou 310006,Zhejiang Province,China;Department of Radiotherapy,Wenzhou Central Hospital,Wenzhou 325000,Zhejiang Province,China;Department of Hematology,Wenzhou Central Hospital,Wenzhou 325000,Zhejiang Province,China)

机构地区：[1]浙江中医药大学滨文校区,310053 [2]浙江大学医学院附属杭州市第一人民医院放疗科,310006 [3]温州市中心医院放疗科,浙江省325000 [4]温州市中心医院血液科,浙江省325000

出　　处：《中国基层医药》2021年第2期174-177,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨血清肺腺癌转移相关转录本1(MALAT1)水平与非小细胞肺癌放疗疗效的关系。方法选择温州市中心医院放疗科2015年1月至2019年12月行根治性放疗非小细胞肺癌患者120例为研究对象,根据放疗剂量将其分为放疗剂量≤60 Gy组53例、放疗剂量>60 Gy组67例;根据疗效分为有效组104例,无效组16例。采用逆转录-聚合酶连反应(RT-PCR)测定各组血清MALAT1水平。结果放疗后MALAT1为(2.31±0.11),高于放疗前的(1.00±0.08),差异有统计学意义(t=105.506,P<0.001);放疗后,放疗剂量>60 Gy组MALAT1水平为(2.52±0.14),高于放疗剂量≤60 Gy组的(1.93±0.12),差异有统计学意义(t=24.395,P<0.001);有效组放疗前MALAT1水平为(0.81±0.06),低于无效组的(1.24±0.07),差异有统计学意义(t=26.095,P<0.001);放疗前MALAT1水平与治疗前截面积呈负相关(r=-0.527,P<0.001)。肿瘤消退率与放疗前MALAT1水平无显著相关性(r=-0.211,P=0.302),与放疗后MALAT1(r=0.467)及放疗前后MALAT1差值(r=0.541)呈正相关(P=0.012、P<0.001)。结论非小细胞肺癌患者放疗后血清MALAT1水平升高,其升高程度与放疗疗效关系密切,在预测放疗疗效中具有一定指导意义。Objective To investigate the relationship between serum metastasis-associated lung adenocarcinoma transcript 1(MALAT1)level and the radiotherapy effect on non-small cell lung cancer.Methods A total of 120 patients with non-small cell lung cancer who received radical radiotherapy in Wenzhou Central Hospital from January 2015 to December 2019 were included in this study.They were divided into radiation dose≤60 Gy group(n=53)and radiation dose>60 Gy group(n=67)according to different radiation doses.They were also divided into an effective group(n=104)and an ineffective group(n=16).Serum MALAT1 level in each group was measured by reverse transcription-polymerase chain reaction.Results After radiotherapy,serum MALAT1 level was(2.31±0.11),which was significantly higher than(1.00±0.08)before radiotherapy(t=105.506,P<0.001).After radiotherapy,serum MALAT1 level in the radiation dose>60 Gy group was significantly higher than that in the radiation dose≤60 Gy group[(2.52±0.14)vs.(1.93±0.12),t=24.395,P<0.001].Before radiotherapy,serum MALAT1 level in the effective group was(0.81±0.06),which was significantly lower than(1.24±0.07)in the ineffective group(t=26.095,P<0.001).Before radiotherapy,serum MALAT1 level was negatively correlated with the cross-sectional area of tumor(r=-0.527,P<0.001).Tumor regression rate was not correlated with serum MALAT1 level before radiotherapy(r=-0.211,P=0.302),but it was positively correlated with serum MALAT1 level after radiotherapy(r=0.467,P=0.012)and the difference of serum MALAT1 level between before and after radiotherapy(r=0.541,P<0.001).Conclusion In patients with non-small cell lung cancer,serum MALAT1 level increases after radiotherapy,which is closely related to the efficacy of radiotherapy.It is of certain guiding significance in predicting the efficacy of radiotherapy.

关 键 词：癌 非小细胞肺 放射疗法 放射治疗剂量 肺腺癌相关转录本1 

分 类 号：R734.2[医药卫生—肿瘤]